This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by deGoma, E. M. Articles by Heidenreich, P. A. Search for Related Content PubMed Articles by deGoma, E. M. Articles by Heidenreich, P. A. Related Collections Related Articles

CLINICAL RESEARCH: LIPIDS AND ATHEROSCLEROSIS

Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol

Emil M. deGoma, MD^_*,_*, Nicholas J. Leeper, MD^_* and Paul A. Heidenreich, MD, MS^_*,

^_* Department of Cardiology, Stanford University Hospital, Stanford, California
Department of Cardiology, Veterans Administration Palo Alto Health Care System, Palo Alto, California.

Manuscript received May 2, 2007; revised manuscript received July 23, 2007, accepted July 24, 2007.

^_* Reprint requests and correspondence: Dr. Emil M. deGoma, 300 Pasteur Drive, Falk Cardiovascular Research Center, Department of Cardiology, Stanford University Hospital, Stanford, California 94305. (Email: edegoma{at}stanford.edu).

Objectives: We sought to evaluate the significance of high-density lipoprotein cholesterol (HDL-C) in the context of low low-density lipoprotein cholesterol (LDL-C).

Background: Earlier studies support an inverse correlation between circulating HDL-C and coronary risk in patients with normal or elevated LDL-C.

Methods: This study involved 4,188 patients attending the Palo Alto Veterans Administration Medical Center or affiliated clinics with LDL-C levels below 60 mg/dl. Outcomes were examined 1 year after the index LDL-C date. The combined primary end point was myocardial injury or hospitalization from ischemic heart disease. The secondary end point was all-cause mortality.

Results: Mean HDL-C levels (mg/dl) by quartile (Q) were: Q1 28 mg/dl, Q2 36 mg/dl, Q3 43 mg/dl, and Q4 63 mg/dl. The rate of myocardial injury or hospitalization for ischemic heart disease showed an inverse relationship to HDL-C (adjusted odds ratios: Q1 1.59 [95% confidence interval (CI) 1.16 to 2.19], Q2 1.39 [95% CI 1.01 to 1.92], Q3 1.33 [95% CI 0.96 to 1.84], and Q4 reference) that persisted regardless of statin use or recent myocardial injury. Analyzing HDL-C as a continuous variable revealed a 10% [95% CI 3% to 17%] increase in the combined end point of myocardial injury or hospitalization for ischemic heart disease for every 10-mg/dl decrease in HDL-C. The unadjusted and adjusted incidence of all-cause mortality demonstrated a U-shaped relationship to HDL-C (adjusted odds ratios: Q1 1.13 [95% CI 0.79 to 1.62], Q2 0.97 [95% CI 0.67 to 1.40], Q3 0.74 [95% CI 0.50 to 1.09], and Q4 reference).

Conclusions: The inverse relationship between HDL-C and coronary risk persists even among patients with LDL-C below 60 mg/dl, although a U-shaped relationship is observed between HDL-C and all-cause mortality.

Abbreviations and Acronyms   HDL-C = high-density lipoprotein cholesterol   ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification   IHD = ischemic heart disease   LDL-C = low-density lipoprotein cholesterol   MI = myocardial infarction   OR = odds ratio   Q = quartile   TnI = troponin I

Related Articles

Shedding Light on High-Density Lipoprotein Cholesterol: The Post-ILLUMINATE Era

Carl J. Lavie and Richard V. Milani
J. Am. Coll. Cardiol. 2008 51: 56-58. [Full Text] [PDF]

This article has been cited by other articles:

				J. Sanz, P. R. Moreno, and V. Fuster The year in atherothrombosis. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337. [Full Text] [PDF]

				I. Goldenberg, V. Boyko, A. Tennenbaum, D. Tanne, S. Behar, and V. Guetta Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate: 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial Arch Intern Med, March 9, 2009; 169(5): 508 - 514. [Abstract] [Full Text] [PDF]

				M. Briel, I. Ferreira-Gonzalez, J. J You, P. J Karanicolas, E. A Akl, P. Wu, B. Blechacz, D. Bassler, X. Wei, A. Sharman, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ, February 16, 2009; 338(feb16_1): b92 - b92. [Abstract] [Full Text] [PDF]

				M. T. Roe, F.-S. Ou, K. P. Alexander, L. K. Newby, J. M. Foody, W. B. Gibler, W. E. Boden, E. M. Ohman, S. C. Smith Jr, and E. D. Peterson Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., October 2, 2008; 29(20): 2480 - 2488. [Abstract] [Full Text] [PDF]

				E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]

				N. J. Leeper, R. Ardehali, E. M. deGoma, and P. A. Heidenreich Response to Letter Regarding Article, "Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival" Circulation, March 4, 2008; 117(9): e175 - e175. [Full Text] [PDF]

				C. J. Lavie and R. V. Milani Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 56 - 58. [Full Text] [PDF]